How long does Advil stay in your system?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
How long does Advil stay in your system?
Advil (Ibuprofen) usually stays in your system for approximately 14-24 hours, as it has a short half-life of about 2-4 hours. This means that the concentration of Advil reduces to half after 2-4 hours (1).
The remaining concentration in your system further reduces to half within the next 2-4 hours (1). This way the drug concentration continues to drop until it is completely eliminated from your body.
Factors affecting the stay time of Advil in your system
The duration of Advil in your system can be influenced by several factors. One significant factor is the dosage and frequency of use. Higher doses and more frequent use of Advil may result in the drug staying in your body for a longer period (2).
Your body’s metabolism and liver function also play a crucial role. People with faster metabolism and healthy liver function may rapidly process and eliminate Advil.
Your age and overall health can also affect how long Advil stays in your system. Younger individuals and those in good health tend to clear the drug more efficiently. Conversely, older individuals or those with certain medical conditions may experience a slower clearance of Advil from their system.
Interactions with other medications can impact the elimination of Advil. Some drugs may interfere with the breakdown of Ibuprofen, either prolonging or shortening its stay time in the body.
Genetic factors can also contribute to individual variations in how long Advil remains in your system. Some people may have genetic traits that affect drug metabolism, leading to differences in drug clearance rates.
How to ensure the safe and effective use of Advil?
To ensure the safe and effective use of Advil (ibuprofen), follow these guidelines: (2,3)
- Read the label: Always read and carefully follow the instructions on the product label. Pay attention to the recommended dosage, frequency, and any special instructions.
- Stick to the recommended dose: Do not exceed the recommended dosage or take Advil more frequently than instructed. Taking higher doses can increase the risk of side effects and complications.
- Avoid long-term use: Advil is intended for short-term relief of pain and inflammation. Prolonged use can lead to adverse effects, such as stomach ulcers and kidney problems. If you need pain relief for an extended period, consult your healthcare provider for alternative solutions.
- Be aware of interactions: Advil may interact with other medications, including prescription drugs and over-the-counter supplements. Inform your healthcare provider about all the medications you are taking to prevent potential interactions.
- Take with food or milk: Advil can irritate the stomach lining, leading to side effects like nausea, heartburn, and abdominal pain. Taking it with food or milk can help reduce this risk.
- Avoid alcohol: Drinking alcohol while using Advil can increase the likelihood of stomach irritation and bleeding. It’s best to abstain from alcohol during Advil use.
- Monitor for side effects: Pay attention to any adverse reactions while taking Advil. Common side effects include upset stomach, heartburn, and dizziness. If you experience severe or persistent side effects, seek medical attention promptly.
- Avoid in certain conditions: Do not take Advil if you have a history of allergies to NSAIDs, stomach ulcers, bleeding disorders, or severe kidney or liver problems.
Remember, Advil is a widely used medication, but it’s essential to use it responsibly and as directed. If you have any concerns or questions about its use, consult your healthcare provider for the best possible advice.
Was this helpful?
References
1.-
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 3672, Ibuprofen; [cited 2023 July 24]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ibuprofen
2.-
Ngo VTH, Bajaj T. Ibuprofen. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31194439. https://www.ncbi.nlm.nih.gov/books/NBK542299
3.-
LABEL: IBUPROFEN tablet, film-coated. DailyMed [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=8ea0e303-3967-4d71-8255-ac42a841ce28&type=pdf
